dx 9065a has been researched along with Thrombosis in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giddings, JC; Hashimoto, M; Oiwa, K; Onobayashi, Y; Yamamoto, J | 1 |
| Chino, D; Fujita, Y; Ishii, K; Nakayama, K | 1 |
| Fareed, J; Hoppensteadt, D; Jeske, WP; Walenga, JM | 1 |
| Alexander, JH; Armstrong, PW; Becker, RC; Berger, PB; Bovill, EG; Buergler, JM; Burton, JR; Chetcuti, S; Cohen, EA; Dyke, CK; Harrington, RA; Hasselblad, V; Hochman, JS; Kleiman, NS; Kunitada, S; Lincoff, AM; Robertson, TL; Saint-Jacques, H; Shimoto, Y; Spence, FP; Yang, H; Zillman, LA | 1 |
| Alexander, J; Becker, RC; Dyke, CK; Harrington, RA | 1 |
| Becker, RC | 1 |
| Furugohri, T; Honda, Y; Isobe, K; Matsumoto, C; Muramatsu, S; Shiozaki, Y; Sugiyama, N | 1 |
| Hanson, SR; Harker, LA; Kelly, AB; Kunitada, S; Marzec, UM; Yokoyama, T | 1 |
| Crain, EJ; Nguan, O; Racanelli, A; Watson, CA; Wong, PC | 1 |
| Giddings, JC; Matsuoka, A; Tsuji, T; Yamamoto, J; Yamashita, T | 1 |
| Boneu, B | 1 |
| Kambayashi, J; Kawasaki, T; Kim, DI; Sakon, M; Shibuya, T | 1 |
| Hara, T; Kunitada, S; Morishima, Y; Tanabe, K; Terada, Y | 1 |
| Aoyagi, K; Hara, T; Kondo, T; Kunitada, S; Morishima, Y; Shibutani, T; Shinohara, Y; Tanabe, K; Terada, Y | 1 |
| Crain, EJ; Knabb, RM; Quan, ML; Watson, CA; Wexler, RR; Wong, PC | 1 |
| Leadley, RJ | 1 |
4 review(s) available for dx 9065a and Thrombosis
| Article | Year |
|---|---|
Factor Xa inhibitors.
Topics: Animals; Anticoagulants; Factor Xa Inhibitors; Heparin; Humans; In Vitro Techniques; Invertebrate Hormones; Lipoproteins; Naphthalenes; Oligosaccharides; Propionates; Recurrence; Thrombosis | 2004 |
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Topics: Animals; Anticoagulants; Area Under Curve; Blood Coagulation; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; International Normalized Ratio; Mice; Models, Biological; Models, Chemical; Naphthalenes; Pilot Projects; Platelet Aggregation Inhibitors; Propionates; Rats; Thrombin; Thromboplastin; Thrombosis; Time Factors | 2004 |
Novel constructs for thrombin inhibition.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Coronary Artery Disease; Drug Design; Endothelium, Vascular; Factor Xa Inhibitors; Heparin; Humans; Naphthalenes; Polysaccharides; Prodrugs; Propionates; Stem Cell Transplantation; Thrombin; Thrombosis | 2005 |
Coagulation factor Xa inhibition: biological background and rationale.
Topics: Animals; Blood Coagulation; Clinical Trials as Topic; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Naphthalenes; Oligosaccharides; Papio; Propionates; Thrombosis | 2001 |
1 trial(s) available for dx 9065a and Thrombosis
| Article | Year |
|---|---|
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
Topics: Aged; Anticoagulants; Blood Coagulation Tests; Cardiac Surgical Procedures; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Feasibility Studies; Female; Heparin; Humans; International Normalized Ratio; Intraoperative Care; Male; Middle Aged; Naphthalenes; Pilot Projects; Postoperative Complications; Propionates; Thrombosis | 2004 |
11 other study(ies) available for dx 9065a and Thrombosis
| Article | Year |
|---|---|
Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo.
Topics: Administration, Oral; Animals; Arterioles; Drug Evaluation, Preclinical; Enzyme Inhibitors; Factor Xa Inhibitors; Fibrinolysis; Fibrinolytic Agents; Image Processing, Computer-Assisted; Infusions, Intravenous; Male; Mesenteric Vascular Occlusion; Microscopy, Video; Naphthalenes; Propionates; Rats; Rats, Wistar; Reproducibility of Results; Thrombolytic Therapy; Thrombosis | 2002 |
Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Topics: Animals; Dose-Response Relationship, Drug; Ellagic Acid; Factor Xa Inhibitors; Hindlimb; Male; Naphthalenes; Nitroarginine; Propionates; Rats; Rats, Wistar; Skin; Skin Diseases; Tetrodotoxin; Thrombosis | 2003 |
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Glycine; Male; Naphthalenes; Propionates; Rats; Rats, Wistar; Thrombin; Thromboplastin; Thrombosis | 2005 |
Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Topics: Administration, Oral; Animals; Arteries; Factor X; Fibrinolytic Agents; Hemostasis; Male; Naphthalenes; Papio; Platelet Aggregation Inhibitors; Propionates; Thrombosis; Veins | 1995 |
Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis.
Topics: Animals; Arthropod Proteins; Factor Xa Inhibitors; Fibrinolytic Agents; Intercellular Signaling Peptides and Proteins; Male; Naphthalenes; Peptides; Propionates; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Thrombosis | 1996 |
The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Topics: Animals; Anticoagulants; Factor Xa Inhibitors; Humans; Injections, Intravenous; Lasers; Male; Microcirculation; Naphthalenes; Propionates; Rats; Rats, Wistar; Thrombosis | 1997 |
[Anti-Xa molecules].
Topics: Animals; Anticoagulants; Arthropod Proteins; Factor Xa Inhibitors; Heparin; Humans; Intercellular Signaling Peptides and Proteins; Invertebrate Hormones; Naphthalenes; Peptides; Polysaccharides; Propionates; Thrombin; Thrombosis | 1996 |
In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Blood Vessel Prosthesis; Disease Models, Animal; Factor Xa Inhibitors; Graft Occlusion, Vascular; Heparin; Male; Microscopy, Electron, Scanning; Naphthalenes; Pipecolic Acids; Propionates; Rabbits; Sulfonamides; Thrombosis | 1996 |
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Topics: Animals; Anticoagulants; Antithrombin III; Arginine; Bleeding Time; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Male; Naphthalenes; Peptide Hydrolases; Pipecolic Acids; Propionates; Rats; Rats, Wistar; Sulfonamides; Thrombin; Thrombosis | 1997 |
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
Topics: Administration, Oral; Animals; Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Male; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Rats; Rats, Wistar; Stomach Ulcer; Tail; Thrombosis | 1999 |
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Topics: Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Humans; In Vitro Techniques; Isoxazoles; Male; Naphthalenes; Platelet Aggregation; Propionates; Rabbits; Recombinant Proteins; Sulfonamides; Tetrazoles; Thrombosis | 2000 |